These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Quinolones: a new class of antimicrobial agents with wide potential uses. Neu HC Med Clin North Am; 1988 May; 72(3):623-36. PubMed ID: 3280910 [TBL] [Abstract][Full Text] [Related]
3. The use of quinolones in respiratory tract infections. Maesen FP; Davies BI; Geraedts WH; Baur C Drugs; 1987; 34 Suppl 1():74-9. PubMed ID: 3325259 [TBL] [Abstract][Full Text] [Related]
4. Systemic anaphylaxis caused by moxifloxacin. Sánchez-Morillas L; Rojas Pérez-Ezquerra P; Reaño-Martos M; Laguna-Martínez JJ; Gómez-Tembleque P Allergol Immunopathol (Madr); 2010; 38(4):226-7. PubMed ID: 20089346 [No Abstract] [Full Text] [Related]
5. New quinolones: their role in clinical practice. Masterton RG Hosp Med; 1999 Feb; 60(2):82-3. PubMed ID: 10320835 [No Abstract] [Full Text] [Related]
6. [Quinolones]. van Ketel RJ Ned Tijdschr Geneeskd; 1987 Aug; 131(34):1467-9. PubMed ID: 3658019 [No Abstract] [Full Text] [Related]
7. Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections. Prescrire Int; 2009 Oct; 18(103):206. PubMed ID: 19882787 [TBL] [Abstract][Full Text] [Related]
8. [Use of new quinolones in respiratory infections]. Sanz Moreno J; Jiménez Rodríguez A Rev Clin Esp; 2000 Dec; 200(12):682-4. PubMed ID: 11234474 [No Abstract] [Full Text] [Related]
9. The potential use of quinolones in future ocular antimicrobial therapy. Borrmann LR; Leopold IH Am J Ophthalmol; 1988 Aug; 106(2):227-9. PubMed ID: 3400767 [No Abstract] [Full Text] [Related]
10. [Moxifloxacin--a novel antimicrobial preparation for treatment of respiratory infections]. Iakovlev SV; Polushkina NR; Iakovlev VP Ter Arkh; 2001; 73(11):15-22. PubMed ID: 11806197 [No Abstract] [Full Text] [Related]
11. Electroconvulsive therapy and antibiotics: a case report. Reti IM; Davydow DS J ECT; 2007 Dec; 23(4):289-90. PubMed ID: 18090707 [TBL] [Abstract][Full Text] [Related]
12. Fluoroquinolones. Molavi A Am Fam Physician; 1988 May; 37(5):279-84. PubMed ID: 3284309 [No Abstract] [Full Text] [Related]
13. [Refractory respiratory tract infections. 7. Trends in the development of new chemotherapeutic agents for respiratory tract infections. b. Synthetic antibacterial agents]. Ohno I; Ida S Nihon Rinsho; 1987 Mar; 45(3):577-82. PubMed ID: 3298736 [No Abstract] [Full Text] [Related]
14. [A new generation of fluoroquinolones--new possibilities for the treatment of respiratory community-acquired infections]. Iakovlev SV Antibiot Khimioter; 2001; 46(6):38-42. PubMed ID: 11573324 [No Abstract] [Full Text] [Related]
15. Treatment of respiratory tract infections with moxifloxacin: results of postmarketing surveillance in China. Liu LY; Landen H Int J Clin Pract; 2007 Sep; 61(9):1509-15. PubMed ID: 17635617 [TBL] [Abstract][Full Text] [Related]
16. [New drugs in the treatment of respiratory infections--the quinolones]. Marta D; Popescu O; Bercea O Rev Ig Med Muncii Med Soc Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1990; 39(2):111-20. PubMed ID: 2131808 [No Abstract] [Full Text] [Related]
17. [Should the use of gyrase inhibitors be limited to hospitals?]. Shah PM Immun Infekt; 1990 Jun; 18(3):69-70. PubMed ID: 2165996 [No Abstract] [Full Text] [Related]
18. [Grepafloxacin (Vaxar)--innovative antibiotic for therapy of respiratory tract infections. Symposium: "Grepafloxacin--a new quinolone designed for respiratory tract infection. Lausanne/Switzerland, 25 May 1997]. Pneumologie; 1997 Sep; 51(9 Suppl):1-4. PubMed ID: 9417540 [No Abstract] [Full Text] [Related]
19. Sparfloxacin, a new generation fluoroquinolone against S. pneumoniae respiratory infections. Niki Y; Tamada S; Nakabayashi M; Soejima R Drugs; 1995; 49 Suppl 2():420-2. PubMed ID: 8549385 [No Abstract] [Full Text] [Related]